UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000005865
Receipt number R000006930
Scientific Title Study for renal outcomes with different combination therapies including Telmisartan in patients with type 2 diabetes and hypertension
Date of disclosure of the study information 2011/06/28
Last modified on 2017/07/11 01:18:01

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Study for renal outcomes with different combination therapies including Telmisartan in patients with type 2 diabetes and hypertension

Acronym

Study for the effect of telmisartan on renal benefits in patients with type 2 diabetes and hypertension

Scientific Title

Study for renal outcomes with different combination therapies including Telmisartan in patients with type 2 diabetes and hypertension

Scientific Title:Acronym

Study for the effect of telmisartan on renal benefits in patients with type 2 diabetes and hypertension

Region

Japan


Condition

Condition

type 2 diabetes mellitus

Classification by specialty

Cardiology Endocrinology and Metabolism Nephrology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To compare the effect on microalbuminuria with three kinds of combination therapies, maximumdose of ARB, standarddose of ARB plus CCB, or standard dose of ARB plus diuretics, in patients with type 2 diabetes and hypertension

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Explanatory

Developmental phase

Phase IV


Assessment

Primary outcomes

Change in urine albumin excretion ratio

Key secondary outcomes

1) blood pressure, 2) HbA1c, plasma glucose, 3) uric acid, 4) urine sodium excretion radio


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

YES

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

YES

Concealment

Numbered container method


Intervention

No. of arms

3

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Telmisartan

Interventions/Control_2

Telmisartan/ Hydrochlorothiazide

Interventions/Control_3

Telmisartan/ Amlodipine

Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1)patients with type 2 diabetes using standard dose of ARB, 2) urine albumin excretion ratio 30-300mg/gCr 3)systolic blood pressure 130-160mmHg 4) HbA1c < 8%(JDS), 5) lipid control is well controlled
6) written informed consent

Key exclusion criteria

1) severe hepatic dysfunction, renal dysfunction, heart failure,
2) history of anaphylaxis of Telmisartan, Hydrochlorothiazide or Amlodipine , 3) pregnancy, 4) patients who are inadequate to enter this study due to the other reasons by physician's judgments

Target sample size

105


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Hideaki Miyoshi

Organization

Hokkaido University Hospital

Division name

Department of Internal Medicine II

Zip code


Address

Nishi 5, Kita 14, Kita-ku, Sapporo, Hokkaido, Japan

TEL

011-706-5915

Email



Public contact

Name of contact person

1st name
Middle name
Last name Hideaki Miyoshi

Organization

Hokkaido University Hospital

Division name

Department of Internal Medicine II

Zip code


Address

Nishi 5, Kita 14, Kita-ku, Sapporo, Hokkaido, Japan

TEL

011-706-5915

Homepage URL


Email

hmiyoshi@med.hokudai.ac.jp


Sponsor or person

Institute

Hokkaido University Hospital

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

北海道大学病院(北海道)、青木内科クリニック(北海道)、大通り内科クリニック(北海道)、小笠原クリニック札幌病院附属外来プラザ(北海道)、沖医院(北海道)、小野百合内科クリニック(北海道)、クラーク病院(北海道)、栗原内科(北海道)、桑園中央病院(北海道)、KKR札幌医療センター斗南病院(北海道)


Other administrative information

Date of disclosure of the study information

2011 Year 06 Month 28 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2011 Year 06 Month 01 Day

Date of IRB


Anticipated trial start date

2011 Year 06 Month 27 Day

Last follow-up date

2016 Year 09 Month 03 Day

Date of closure to data entry

2016 Year 09 Month 03 Day

Date trial data considered complete

2016 Year 09 Month 03 Day

Date analysis concluded

2016 Year 09 Month 10 Day


Other

Other related information



Management information

Registered date

2011 Year 06 Month 28 Day

Last modified on

2017 Year 07 Month 11 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006930